目的 探究苦碟子注射液聯(lián)合曲美他嗪治療冠心病心絞痛的臨床療效。方法 選取2018年1月-2020年12月河南科技大學(xué)第一附屬醫(yī)院收治的100例冠心病患者，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組口服鹽酸曲美他嗪片，20 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上靜脈注射苦碟子注射液，30 mL加入250 mL生理鹽水，1次/d。兩組患者連續(xù)治療1個(gè)月。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善情況、血漿纖維蛋白原、血漿黏度、中醫(yī)癥候評(píng)分。結(jié)果 治療后，治療組臨床有效率為92.00%，顯著高于對(duì)照組的82.00%（P<0.05）。治療后，兩組患者心絞痛發(fā)作頻率和持續(xù)時(shí)間以及硝酸甘油用量均明顯減少（P<0.05），且治療組明顯少于對(duì)照組（P<0.05）。治療后，兩組患者血漿纖維蛋白原和血漿黏度水平明顯下降（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。治療后，兩組中醫(yī)癥候評(píng)分明顯下降（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。結(jié)論 苦碟子注射液聯(lián)合曲美他嗪治療冠心病心絞痛能夠改善患者臨床癥狀和血液流變學(xué)指標(biāo)，提高臨床有效率。

Objective To explore the efficacy of Kudiezi Injection combined with trimetazidine in treatment of angina pectoris of coronary heart disease. Methods Patients (100 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Henan Science & Technology University from January 2018 to December 2020 were randomly divided into control (50 cases) and treatment (50 cases) groups. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were iv administered with Kudiezi Injection, 30 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, the improvement of clinical symptoms, plasma fibrinogen, plasma viscosity, and the TCM syndrome scores in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 92.00%, which was significantly higher than 82.00% in the control group (P<0.05). After treatment, the frequency and duration of angina pectoris and the dosage of nitroglycerin in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly less than those in the control group (P<0.05). After treatment, plasma fibrinogen and plasma viscosity levels in two groups were significantly decreased (P<0.05), and the treatment group was significantly lower than the control group (P<0.05). After treatment, the TCM syndrome score in two groups were significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Kudiezi injection combined with trimetazidine in the treatment of patients with angina pectoris of coronary heart disease can improve clinical symptoms and hemodynamic indicators, and improve clinical effectiveness.

R972

河南科技大學(xué)青年科學(xué)基金資助項(xiàng)目（2018QN047）